Transverse MyelitisSymptoms, Doctors, Treatments, Advances & More
Transverse Myelitis Overview
Learn About Transverse Myelitis
Transverse myelitis is a rare neurological condition marked by inflammation that spans across both sides of a segment of the spinal cord. This inflammation damages the myelin sheath, the protective covering of nerve fibers, and disrupts the normal transmission of nerve signals. It can occur in individuals of any age, gender, or ethnicity, though it most often affects young and middle-aged adults.
Because of its significant impact on motor, sensory, and autonomic functions, recognizing transverse myelitis early is critical. Timely management can reduce long-term disability and improve outcomes. This article explores transverse myelitis in detail, examining its causes, symptoms, diagnosis, treatment, prognosis, and prevention.
Transverse myelitis is an inflammatory disorder of the spinal cord that typically affects both sides of a spinal segment. The term “transverse” reflects that inflammation often spans the width of the spinal cord, disrupting motor, sensory, and autonomic pathways below the lesion. This can result in weakness, sensory disturbances, and impaired bowel or bladder control.
It is a neurological emergency requiring rapid recognition and intervention. On clinical examination, physicians often detect a sensory level corresponding to the spinal lesion. While transverse myelitis can occur at any level, the thoracic spinal cord is most commonly affected.
Transverse myelitis can develop from multiple causes. It may occur on its own or as part of another systemic or neurological condition.
- Idiopathic transverse myelitis: occurs without an identifiable cause and represents a large portion of cases
- Post-infectious or parainfectious: follows a viral or bacterial infection such as herpesviruses, influenza, or Mycoplasma pneumoniae; thought to result from an autoimmune reaction
- Autoimmune disorders: linked with systemic lupus erythematosus, Sjögren’s syndrome, sarcoidosis, or mixed connective tissue disease
- Demyelinating diseases: includes multiple sclerosis, neuromyelitis optica spectrum disorder, or MOG antibody disease
- Paraneoplastic syndromes: rare cases due to immune responses related to cancer
- Vaccination-related: extremely rare instances possibly triggered by an immune reaction
- Other causes: vascular myelopathy, direct infection (HIV, syphilis, tuberculosis), or radiation-induced myelopathy
The development of transverse myelitis typically involves an inflammatory attack on the spinal cord. This process damages the myelin sheath and sometimes the axons, impairing the transmission of nerve signals. Inflammation may result from immune system dysfunction or direct invasion of infectious agents.
The clinical features depend on the level of the spinal cord involved. Cervical lesions may affect both arms and legs, thoracic lesions usually impair the lower body, and lumbar lesions often impact lower limb and autonomic function. MRI is often used to identify spinal lesions, with longitudinally extensive transverse myelitis (covering three or more vertebral segments) suggesting conditions like neuromyelitis optica spectrum disorder, while shorter lesions may indicate multiple sclerosis.
Symptoms of transverse myelitis often progress over hours to days, though sometimes over weeks. The hallmark is bilateral neurological deficits below the affected spinal level.
- Motor symptoms: weakness of the limbs, difficulty walking, spasticity, hyperreflexia, or Babinski sign
- Sensory symptoms: numbness, tingling, defined sensory level, pain, or loss of proprioception
- Autonomic dysfunction: urinary retention, bowel changes, sexual dysfunction
- Pattern and progression: rapid onset, bilateral deficits, sometimes asymmetry, back pain often precedes neurological deficits
A detailed diagnostic process is needed to confirm transverse myelitis, identify its cause, and rule out other conditions like spinal compression.
- Clinical examination: neurological exam to identify motor, sensory, and autonomic deficits, plus determination of sensory level
- MRI: visualizes inflammation and excludes compressive causes; lesions appear as signal changes on T2-weighted imaging
- Lumbar puncture: may reveal increased protein, white cells, or oligoclonal bands
- Blood tests: autoimmune markers, aquaporin-4 antibodies, MOG antibodies, infectious serologies
- Additional tests: somatosensory or visual evoked potentials in select cases
Treatment depends on the cause, but rapid anti-inflammatory therapy is essential in most cases.
- Acute management: high-dose IV corticosteroids, plasma exchange if unresponsive to steroids, IV immunoglobulin in some cases
- Targeted therapy: antivirals or antibiotics for infections, immunosuppressive medications for autoimmune disorders
- Supportive care: prevent complications such as pressure ulcers or blood clots, bladder catheterization, pain management
- Rehabilitation: physical therapy to improve mobility, occupational therapy for daily living, psychological support
The prognosis of transverse myelitis is variable, with recovery ranging from complete restoration to severe permanent disability.
- Recovery outcomes: one-third of patients fully recover, one-third retain moderate deficits, and one-third experience severe disability
- Poorer prognosis: rapid symptom progression, complete motor loss at peak, lack of early recovery, or longitudinally extensive lesions
- Recurrence: higher risk in cases linked with neuromyelitis optica spectrum disorder or systemic autoimmune disease
Most cases of transverse myelitis cannot be prevented, but risk can be reduced in some situations.
- Prompt treatment of infections
- Careful management of autoimmune diseases
- Monitoring in conditions like neuromyelitis optica spectrum disorder
- Early medical evaluation of new neurological symptoms
Transverse myelitis is a serious spinal cord disorder that causes significant motor, sensory, and autonomic dysfunction. Because of its broad range of causes and potential for lasting disability, early recognition and treatment are crucial. Long-term management should focus on addressing underlying causes and maximizing recovery through rehabilitation and supportive care.
- Frohman EM, Wingerchuk DM. Transverse myelitis. New England Journal of Medicine. 2010;363(6):564-572.
- Jacob A, Weinshenker BG. An approach to the diagnosis of acute transverse myelitis. Seminars in Neurology. 2008;28(1):105-120.
- Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurologic Clinics. 2013;31(1):79-138.
- Scott TF, Kassab SL. Transverse myelitis. Current Treatment Options in Neurology. 1999;1(2):99-104.
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Scott Newsome is a Neurologist practicing medicine in Lutherville, Maryland. Dr. Newsome is rated as an Elite provider by MediFind in the treatment of Transverse Myelitis. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Stiff Person Syndrome, Multiple Sclerosis (MS), Transverse Myelitis, and Relapsing Multiple Sclerosis (RMS). Dr. Newsome is board certified in American Board Of Psychiatry And Neurology. Dr. Newsome is currently accepting new patients.
Neuroscience Center – Specialty Clinics
Ahmed Obeidat is a Neurologist practicing medicine in Milwaukee, Wisconsin. Dr. Obeidat is rated as a Distinguished provider by MediFind in the treatment of Transverse Myelitis. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Transverse Myelitis, and Optic Neuritis. Dr. Obeidat is board certified in Neurology. Dr. Obeidat is currently accepting new patients.
Kazuo Fujihara practices practicing medicine in Fukushima, Japan. Mr. Fujihara is rated as an Elite expert by MediFind in the treatment of Transverse Myelitis. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Neuromyelitis Optica, Transverse Myelitis, Optic Neuritis, Myelitis, and Thymectomy.
Summary: This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen receptor (CAR)-targeted B-cell activating factor receptor (BAFFR) in refractory neuroimmune diseases. The study design is divided into two parts, the first of which will be given to each patient at 3 incremental dose levels to ...
Summary: This is an observational study to: * evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure), * enhance knowledge regarding conventional MRI outcomes in people with NMOSD treated with ravulizumab, * identify factors suggestive of subclinical disease progression through conventional MRI sequences, * determine if trea...

